GlassScriptPhysician profile
Usman Ansari
NPI 1053977157
$2,136.80
in general payments reported to CMS, 2019-2025
16 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $445 · 2024: $569 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Education: $16.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.86 |
| Education | $16.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.57 | 2024-2025 | |
| Janssen Biotech, INC. | $388.47 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $260.65 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $202.50 | 2023-2024 | Dupixent |
| Ardelyx, INC. | $181.89 | 2023-2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.59 | 2024-2025 | Xifaxan |
| Genzyme Corporation | $138.15 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $101.79 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $89.41 | 2025 | Rezdiffra |
| Celltrion USA INC. | $51.58 | 2023-2025 | Vegzelma, Yuflyma |
| Merck Sharp & Dohme LLC | $33.71 | 2023 | Dificid, Recarbrio, Zerbaxa |
| Lilly USA, LLC | $30.01 | 2025 | Omvoh |
| Novo Nordisk INC | $22.40 | 2025 | Wegovy |
| Gilead Sciences, INC. | $22.15 | 2025 | |
| Pfizer INC. | $20.30 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16.63 | 2023 | Exalt Model D |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.